Japan Pharma Gearing Up For Battle In Reimbursement Talks As Tax Landscape Shifts
This article was originally published in PharmAsia News
Increased consumption tax and tax credits for R&D offer a new playing field as 2014 price revision talks take shape.
You may also be interested in...
European Regulatory Round-Up: EMA And The UK Heed The Calls Of Industry; France Is Otherwise Occupied
The European Medicines Agency follows through on its transparency initiative with comprehensive list of products under review and also reduces pharmacovigilence data reporting requirements.
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?